Alkeus Pharmaceuticals’ study results from Gildeuretinol shows significant trend in slowing geographic atrophy: Cambridge, Massachusetts Friday, October 25, 2024, 10:00 Hrs [IST ...

Preliminary data from a late stage clinical trial of a retinal implant showed promising results, Science Corporation said ...

Sunir Garg, MD, shares insights on new data on aflibercept 8 mg, faricimab, and the impact of social determinants of health, ...

There are various factors that may potentially increase the risk of developing AMD, such as advancing age (over 50); having a ...

Age-related macular degeneration (AMD) is one of the leading causes of vision ... researchers are still looking for more accessible and affordable treatments for all forms of AMD. Since AMD is closely ...

A new statistical models shed light on why some patients can extend the dosing interval with Eylea (aflibercept) from 8 weeks ...

While adverse events (AEs) were reported for 97% of trial participants, such cases were predominantly mild to moderate.

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive topline one-year results from ...

The ELEVATUM study showed clinically meaningful improvement in vision and reduction in retinal fluid in people with diabetic ...

SOL-1 is now expected to be enrolled and fully randomized by year-end 2024. Topline clinical data from SOL-1 are now expected in Q4 2025. BEDFORD, Mass., Oct. 15, 2024 (GLOBE NEWS ...

Other reasons for using thyroid hormone therapy may rarely include: To control the growth of the enlarged thyroid gland (also called goiter) To control the growth of nodules on the thyroid gland ...

With wet age-related macular degeneration (AMD), prompt treatment is crucial to help minimize ... anti-VEGF injections are currently the best available options to prevent further losses to your ...